Domingo A Pascual-Figal1,2,3, Maria T Pérez-Martínez1,4, Maria C Asensio-Lopez1, Jesús Sanchez-Más5, Maria E García-García6, Carlos M Martinez4, Miriam Lencina7, Ruben Jara6, James L Januzzi8, Antonio Lax4. 1. Department of Cardiology, Hospital Virgen de la Arrixaca, University of Murcia, Spain (D.A.P.-F., M.T.P.-M., M.C.A.-L., A.L.). 2. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (D.A.P.-F.). 3. CIBERCV, Madrid, Spain (D.A.P.-F.). 4. IMIB-Arrixaca, University of Murcia, Spain (M.T.P.-M., M.C.A.-L., C.M.M., A.L.). 5. Departamento de Ciencias Biomédicas, Universidad CEU Cardenal Herrera, Moncada, Valencia, Spain (J.S.-M.). 6. Servicio de Medicina Intensiva, Hospital Virgen de la Arrixaca, Hospital Virgen de la Arrixaca, Murcia, Spain (M.E.G.-G., R.J.). 7. Department of Pathological Anatomy, Hospital Virgen de la Arrixaca, Murcia, Spain (M.L.). 8. Division of Cardiology, Massachusetts General Hospital, Baim Institute for Clinical Research, Boston (J.L.J.).
Abstract
BACKGROUND: Serum concentrations of ST2 (interleukin-1 receptor-like 1) represent a meaningful prognostic marker in cardiac diseases. Production of soluble ST2 (sST2) may be partially extracardiac. Identification of sST2 sources is relevant to design strategies for modulating its signaling. METHODS AND RESULTS: An experimental model of ischemic heart failure was used. sST2, membrane-bound ST2 (ST2L), and IL-33 were measured in lungs, heart, kidney, and liver by quantifying mRNA and protein expression in tissue samples obtained at different times (1, 2, 4, and 24 weeks). Primary human type II pneumocyte cell cultures were subjected to strain. sST2 was measured in samples of bronchial aspirate and serum obtained from patients treated with invasive respiratory support. In the experimental model, sST2 increased significantly from the first week in both lungs and myocardium, whereas ST2L/IL-33 response was unfavorable in lungs (decrease) and favorable in myocardium (increase). No changes were observed in liver and kidneys. ST2 immunostaining was intensely observed in alveolar epithelium, and sST2 was secreted by primary human type II pneumocytes in response to strain. sST2 levels in lung aspirates were substantially higher in the presence of cardiogenic pulmonary edema (median, 228 [interquartile range, 28.4-324.0] ng/mL; P<0.001) than bronchopneumonia (median, 5.5 [interquartile range, 1.6-6.5]) or neurological disorders (median, 2.9 [interquartile range, 1.7-10.1]), whereas sST2 concentrations in serum did not differ. CONCLUSIONS: The lungs are a relevant source of sST2 in heart failure. These results may have implications for the progression of disease and the development of therapies targeting the ST2 system in patients with heart failure.
BACKGROUND: Serum concentrations of ST2 (interleukin-1 receptor-like 1) represent a meaningful prognostic marker in cardiac diseases. Production of soluble ST2 (sST2) may be partially extracardiac. Identification of sST2 sources is relevant to design strategies for modulating its signaling. METHODS AND RESULTS: An experimental model of ischemic heart failure was used. sST2, membrane-bound ST2 (ST2L), and IL-33 were measured in lungs, heart, kidney, and liver by quantifying mRNA and protein expression in tissue samples obtained at different times (1, 2, 4, and 24 weeks). Primary human type II pneumocyte cell cultures were subjected to strain. sST2 was measured in samples of bronchial aspirate and serum obtained from patients treated with invasive respiratory support. In the experimental model, sST2 increased significantly from the first week in both lungs and myocardium, whereas ST2L/IL-33 response was unfavorable in lungs (decrease) and favorable in myocardium (increase). No changes were observed in liver and kidneys. ST2 immunostaining was intensely observed in alveolar epithelium, and sST2 was secreted by primary human type II pneumocytes in response to strain. sST2 levels in lung aspirates were substantially higher in the presence of cardiogenic pulmonary edema (median, 228 [interquartile range, 28.4-324.0] ng/mL; P<0.001) than bronchopneumonia (median, 5.5 [interquartile range, 1.6-6.5]) or neurological disorders (median, 2.9 [interquartile range, 1.7-10.1]), whereas sST2 concentrations in serum did not differ. CONCLUSIONS: The lungs are a relevant source of sST2 in heart failure. These results may have implications for the progression of disease and the development of therapies targeting the ST2 system in patients with heart failure.
Authors: Jonathan Beaudoin; Jackie Szymonifka; Zachary Lavender; Roderick C Deaño; Qing Zhou; James L Januzzi; Jagmeet P Singh; Quynh A Truong Journal: J Thorac Dis Date: 2019-12 Impact factor: 2.895
Authors: Jehan Alladina; Sean D Levy; Josalyn L Cho; Kelsey L Brait; Sowmya R Rao; Alexander Camacho; Kathryn A Hibbert; R Scott Harris; Benjamin D Medoff; James L Januzzi; B Taylor Thompson; Ednan K Bajwa Journal: Am J Respir Crit Care Med Date: 2021-05-15 Impact factor: 21.405
Authors: Torbjorn Omland; Christian Prebensen; Christine Jonassen; My Svensson; Jan Erik Berdal; Ingebjørg Seljeflot; Peder Langeland Myhre Journal: Open Heart Date: 2021-12
Authors: Jehan W Alladina; Francesca L Giacona; Emma B White; Kelsey L Brait; Elizabeth A Abe; Sam A Michelhaugh; Kathryn A Hibbert; James L Januzzi; B Taylor Thompson; Josalyn L Cho; Benjamin D Medoff Journal: Crit Care Explor Date: 2021-06-29